From Sankyo’s experience, Roger Newton and his pharmacology colleagues at Parke-Davis learned that the rat is not a good animal model for cholesterol-lowering drugs because the rat’s liver is able to rapidly compensate for the drop of cholesterol. So, for initial in vivo efficacy studies, Newton’s team chose guinea pigs and divided them into two sets: one normal group and the other a chow-fed group. The pharmacologists then gave different groups of guinea pigs Merck’s Mevacor (lovastatin) as a reference or CI-981 in one of three different doses. When the results were tabulated, Parke-Davis scientists were underwhelmed: not only was CI-981 no better than lovastatin in lowering cholesterol, but it seemed even a little inferior. However, they continued with the animal studies with a higher species—the dog. They used cholestyramine-primed dogs since the plasma cholesterol-lowering effects became more pronounced after the dogs had been fed with the cholesterol-lowering resin. Unfortunately, again in dogs, CI-981 showed LDL-cholesterol–lowering efficacy about the same as that of lovastatin at the doses tested. Upon further scrutiny of the data, the only advantage that the pharmacologists could fi nd was that CI-981 lowered triglyceride levels slightly better (20–40%) than lovastatin in those animal models. In 1988, Mevacor had already been on the market for an entire year. Merck’s Zocor and Bristol-Myers Squibb’s Pravachol were poised to be launched in 1991, and Sandoz’s Lescol would be ready to launch in 1994. In addition, Rhône- Poulenc Rorer’s dalvastatin was at a similar stage as CI-981 in development. Either dalvastatin or CI-981 would have become the fifth of its kind on the market. Parke-Davis believed that they would need differentiation in order to successfully sell its drug. After all, CI-981 had to be different from, hopefully better than, existing drugs, for them to make a good profit. Parke-Davis’s belief that they needed to differentiate CI-981 from existing statins had its root in another Parke-Davis drug, Accupril (quinapril), an ACE inhibitor poised to launch in 1991.